ABSTRACT
BACKGROUND: Although the evaluation of fluid status in hemodialysis (HD) patients is useful, relationship among pulmonary capillary wedge pressure (PCWP), dry body weight (DW) and natriuretic peptide has not been elucidated. In addition, there has been no objective marker for instantaneously monitoring hemodynamic improvement in response to HD. We previously reported that PCWP and time constant of left ventricular pressure decline (Tau) can be noninvasively estimated (ePCWP and eTau) by speckle tracking echocardiography (STE). The aim of this study was to elucidate the relationship among ePCWP, eTau, DW and natriuretic peptide in patients undergoing HD. METHODS: We measured ePCWP and body weight (BW) by STE in 81 patients and ANP and BNP by blood examination in 31 patients just before and after HD during sinus rhythm. RESULTS: The ePCWP decreased after HD, and this was associated with reductions in ln ANP, eTau and BW (r = 0.523, 0.271 and 0.814, respectively, p < 0.05). The % change in ePCWP was not correlated with the % change in ln BNP (p = 0.47). The change in ePCWP had a stronger correlation with the % change in BW than the change in any other parameters. CONCLUSIONS: The ePCWP is more sensitive to estimate the change in BW during HD than any other parameters such as ANP and BNP. These results indicated that a substantial amount of excess fluid can be assessed real-time by STE using ePCWP.
Subject(s)
Echocardiography, Three-Dimensional/methods , Hemodynamics , Kidney Failure, Chronic/diagnostic imaging , Kidney Failure, Chronic/therapy , Renal Dialysis , Aged , Biomarkers/blood , Body Weight , Female , Humans , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/physiopathology , Male , Middle Aged , Natriuretic Peptide, Brain/blood , Natriuretic Peptides/blood , Pulmonary Wedge PressureABSTRACT
PURPOSES: Acute exacerbation of interstitial pneumonia (AEIP) is a leading cause of death after lung cancer resection in patients with interstitial lung disease. METHODS: We retrospectively analyzed 1763 patients with non-small cell lung cancer with a clinical diagnosis of interstitial lung disease (ILD) who underwent lung cancer resection between 2000 and 2009 at 61 hospitals in Japan. AEIP occurred in 164 of 1763 (9.3%) patients with a mortality rate of 43.9% (72/164). Univariate and multivariate analyses were carried out to identify possible risk factors of fatal AEIP. We then analyzed the 164 patients who developed postoperative AEIP and identified the preoperative and postoperative risk factors. RESULTS: A multivariate regression analysis identified that the sex, percent vital capacity, neoadjuvant radiation, preoperative history of AEIP, preoperative use of steroids, usual interstitial pneumonia pattern on CT, and surgical procedures were independent preoperative risk factors for death due to AEIP. ILD patients with emphysema somehow showed a lower risk of fatal AEIP than those without emphysema in this study. CONCLUSIONS: This study revealed eight risk factors for fatal AEIP.
Subject(s)
Carcinoma, Non-Small-Cell Lung/complications , Carcinoma, Non-Small-Cell Lung/mortality , Disease Progression , Lung Diseases, Interstitial/etiology , Lung Diseases, Interstitial/mortality , Lung Neoplasms/complications , Lung Neoplasms/mortality , Lung Neoplasms/surgery , Pneumonectomy , Acute Disease , Adult , Aged , Aged, 80 and over , Analysis of Variance , Carcinoma, Non-Small-Cell Lung/surgery , Cause of Death , Female , Humans , Male , Middle Aged , Neoadjuvant Therapy , Pulmonary Emphysema , Retrospective Studies , Risk Factors , Sex Factors , Tomography, X-Ray Computed , Vital CapacityABSTRACT
We evaluated the feasibility of maintenance treatment using UFT (a combination of tegafur and uracil) after adjuvant platinum-based chemotherapy in patients with resected lung cancer. A prospective feasibility trial was conducted. Between 2010 and 2014, UFT was administered for 2 years sequentially after platinum-based adjuvant chemotherapy in 24 patients with resected Stage IIA-IIIA non-small cell lung cancer. The safety of UFT and the rate of treatment completion were then evaluated. The prior platinum-based chemotherapy regimens consisted of cisplatin+vinorelbine in 16 patients, carboplatin+paclitaxel in 5 and carboplatin+S-1 in one. During the subsequent UFT administration, a total of 3 patients required a dose reduction because of Grade 1 blood-stained sputum, Grade 2 numbness, and Grade 2 constipation, in one patient each. Eleven patients underwent the planned 2-year UFT administration, but 12 patients could not because of the recurrence of lung cancer in 5 patients, metachronous malignancy in one, and toxicities in 6. The completion rate for UFT administration was 64.7% (11/17). The most common type of toxicity was gastrointestinal toxicities. All of the toxicities were grade 1 or 2, and no severe toxicities were observed. UFT treatment after platinum-based chemotherapy was revealed to be feasible.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Non-Small-Cell Lung/drug therapy , Lung Neoplasms/drug therapy , Administration, Oral , Adult , Aged , Aged, 80 and over , Chemotherapy, Adjuvant , Feasibility Studies , Female , Humans , Male , Middle Aged , Platinum/therapeutic use , Tegafur/therapeutic use , Uracil/therapeutic useABSTRACT
BACKGROUND: The long-term outcomes of follow-up care for ground-glass opacity (GGO) lesions need to be clarified. METHODS: Between 2000 and 2005, a total of 226 patients with pure or mixed GGO lesions ≤ 3 cm in size were registered. The CT findings and changes in the findings during the follow-up period and the outcomes of the 226 patients were subsequently reviewed. RESULTS: Overall, 124 patients underwent resections, 57 did not receive follow-up examinations after 68 months because of stable disease or disease reduction, and 45 are continuing to receive follow-up examinations. Thirty-nine patients exhibited tumor growth during the follow-up period. Among the patients with a ratio of the diameter of consolidation relative to the tumor diameter (CTR) > 0, all cases with tumor growth were identified within 3 years; meanwhile, > 3 years were required to identify tumor growth in 16% of the patients with a CTR of 0. Aggressive cancer occurred in 4% of patients with a CTR of 0 and in 70% of patients with a CTR > 25%. Aggressive cancer was observed in 46% of the patients whose CTR increased during the follow-up period and in 8% of the patients whose tumors increased in size. CONCLUSIONS: A higher CTR and an increase in CTR during follow-up were associated with invasive cancer. A follow-up period of 3 years is considered to be adequate for judging tumor growth in patients with a CTR > 0, whereas a longer follow-up period might be needed for patients with a CTR of 0.
Subject(s)
Adenocarcinoma in Situ/diagnostic imaging , Adenocarcinoma/diagnostic imaging , Lung Neoplasms/diagnostic imaging , Lung/diagnostic imaging , Adenocarcinoma/surgery , Adenocarcinoma in Situ/surgery , Adult , Aged , Aged, 80 and over , Female , Follow-Up Studies , Humans , Lung/surgery , Lung Neoplasms/surgery , Male , Middle Aged , Pneumonectomy , Retrospective Studies , Time Factors , Tomography, X-Ray Computed , Watchful Waiting , Young AdultABSTRACT
BACKGROUND/OBJECTIVE: The concept of salvage pulmonary resection after definitive chemoradiotherapy (dCRT) is not yet commonly accepted in lung cancer treatment. We report our experience of eight patients in whom we performed salvage pulmonary resection for residual disease or isolated locoregional recurrence detected after dCRT. METHODS: Between 2005 and 2014, we performed salvage pulmonary resection for eight patients with N2 Stage-IIIA non-small cell lung cancer. The patients had initially received dCRT (radiation ≤ 60 Gy), but eventually underwent pulmonary resection with curative intent for residual disease or isolated locoregional recurrence. The postoperative complications, incidence of recurrence, and survival parameters were evaluated. RESULTS: Salvage pulmonary resection was performed in four patients with residual disease and four patients with locoregional recurrence. Complete resection was successfully performed in all eight patients. Postoperative complications were observed in three patients, however, there were no postoperative mortalities. One patient developed local recurrence in a mediastinal lymph node and two patients died. Of the two fatalities, one was related to lung cancer. The estimated 5-year survival rate of the eight patients was 75.0%. CONCLUSION: We report our experience of salvage pulmonary resection performed for residual disease or isolated locoregional recurrence diagnosed after dCRT in eight patients with locally advanced lung cancer. Although the postoperative complication rate was high, the survival data were favorable. A larger study is needed to confirm the safety and feasibility of salvage pulmonary resection after dCRT.
Subject(s)
Chemoradiotherapy/methods , Lung Neoplasms/pathology , Lung Neoplasms/therapy , Neoplasm, Residual/surgery , Pneumonectomy/methods , Salvage Therapy/methods , Adenocarcinoma/mortality , Adenocarcinoma/pathology , Adenocarcinoma/therapy , Aged , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/therapy , Disease-Free Survival , Female , Humans , Japan , Kaplan-Meier Estimate , Lung Neoplasms/mortality , Male , Middle Aged , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/surgery , Pneumonectomy/mortality , Prognosis , Retrospective Studies , Risk Assessment , Sampling Studies , Survival Analysis , Treatment OutcomeABSTRACT
We reviewed post-operative complication and mortality rates from 1995 through 2014 and evaluated the changes in those rates across that 20-year period. Two thousand and three hundred sixteen patients with lung cancer underwent resection at our institution between 1995 and 2014. This timespan was divided into four 5-year periods. Each patient's age, Charlson comorbidity index score, and extent of surgery in each 5-year period were summarized, and the changes in these factors over the 20-year span were evaluated. The complication and mortality rates were calculated for each 5-year period, and the changes in those rates over the 20-years were evaluated. The number of patients with higher Charlson comorbidity index scores increased during the 20-year period. Of the 455 patients who developed complications, 97 developed life-threating complications. There were 16 post-operative deaths and 23 in-hospital deaths. There were no significant changes in the complication rate or mortality rate during the 20-year period. Both rates were significantly correlated with the extent of resection. Although the number of patients with comorbidities increased in the 20-year period, the post-operative complication and mortality rates, as well as in-hospital mortality, did not change significantly.
Subject(s)
Lung Neoplasms/surgery , Postoperative Complications/mortality , Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Retrospective Studies , Young AdultABSTRACT
INTRODUCTION: Usefulness of complete metastasectomy against pulmonary metastases from renal cell carcinoma (RCC) is well known. We examined the efficacy of surgical resection of pulmonary metastases from RCC performed in Shikoku Cancer Center. METHOD: Between January 2004 and December 2014, 11 patients with pulmonary metastases from RCC underwent thoracic resection in our institution. We examined disease-free interval (DFI) and overall survival of these patients after pulmonary metastasectomy. RESULTS: Patients included 9 men and 2 women with a mean age of 63.2 years. The median number of metastases was 1 (range 1-6). Overall, 5 patients had a single metastasis (45.5%), 8 patients had unilateral metastases (72.7%), and 3 patients received immunotherapy or chemotherapy in the interval between radical nephrectomy and pulmonary metastasectomy. We performed complete pulmonary metastasectomy in these patients. The median observation period was 43 months (range 5-82), median DFI was 5 months (range 2-17), and 3-year overall survival rate was 86%. In the 3 patients who had primary or metastatic tumors with sarcomatoid (SA) component, their median DFI tended to be shorter than that of 8 patients without it (2 vs. 8 months, p = 0.07). CONCLUSION: The pulmonary metastasectomy for RCC is a treatment option, while the indication for RCC with SA component should be carefully considered.
Subject(s)
Carcinoma, Renal Cell/secondary , Kidney Neoplasms/pathology , Lung Neoplasms/secondary , Metastasectomy/methods , Pneumonectomy/methods , Biopsy , Carcinoma, Renal Cell/diagnosis , Carcinoma, Renal Cell/surgery , Disease-Free Survival , Female , Humans , Japan/epidemiology , Kidney Neoplasms/mortality , Kidney Neoplasms/surgery , Lung Neoplasms/diagnosis , Lung Neoplasms/surgery , Male , Metastasectomy/mortality , Middle Aged , Pneumonectomy/mortality , Prognosis , Survival Rate/trends , Tomography, X-Ray ComputedABSTRACT
A large number of studies have demonstrated that 2-deoxy-2-[fluorine-18]fluoro-d-glucose positron emission tomography/computed tomography (FDG-PET/CT) is superior to conventional modalities for the diagnosis of lung cancer and the evaluation of the extent of the disease. However, the efficacy of PET/CT in a follow-up surveillance setting following curative-intent treatments for lung cancer has not yet been established. We reviewed previous papers and evaluated the potential efficacy of PET-CT in the setting of follow-up surveillance. The following are our findings: 1) PET/CT is considered to be superior or equivalent to conventional modalities for the detection of local recurrence. However, inflammatory changes and fibrosis after treatments in local areas often result in false-positive findings; 2) the detection of asymptomatic distant metastasis is considered to be an advantage of PET/CT in a follow-up setting. However, it should be noted that detection of brain metastasis with PET/CT has some limitation, similar to its use in pretreatment staging; 3) additional radiation exposure and higher medical cost arising from the use of PET/CT should be taken into consideration, particularly in patients who might not have cancer after curative-intent treatment and are expected to have a long lifespan. The absence of any data regarding survival benefits and/or improvements in quality of life is another critical issue. In summary, PET/CT is considered to be more accurate and sensitive than conventional modalities for the detection of asymptomatic recurrence after curative-intent treatments. These advantages could modify subsequent management in patients with suspected recurrence and might contribute to the selection of appropriate treatments for recurrence. Therefore, PET/CT may be an alternative to conventional follow-up modalities. However, several important issues remain to be solved. PET/CT in a follow-up surveillance setting is generally not recommended in clinical practice at the moment.
ABSTRACT
A 35-year-old Japanese man's routine chest radiography revealed an abnormal opacity. Chest computed tomography and magnetic resonance imaging showed a 5.5 cm in dia. cystic tumor located at the left anterior mediastinum. The tumor was suspected to be an asymptomatic thymic cyst, and we chose observation for the tumor. At the 3-year follow up, the cystic tumor had gradually enlarged to 7.5 cm in dia. and we thus performed a surgical resection via left video-assisted thoracic surgery. An immunohistochemical analysis showed that the cystic tumor was not a thymic cyst but rather a mediastinal cystic lymphangioma. Mediastinal cystic lymphangiomas are very rare, and they are difficult to diagnose preoperatively. Complete surgical resection is proposed for the treatment of such tumors.
Subject(s)
Lymphangioma, Cystic/pathology , Mediastinal Neoplasms/pathology , Adult , Humans , Lymphangioma, Cystic/diagnosis , Magnetic Resonance Imaging , Male , Mediastinal Neoplasms/diagnosis , Tomography, X-Ray ComputedABSTRACT
Inflammatory myofibroblastic tumor (IMT) is a rare neoplasm that occurs at different sites in the body. Pleural IMT in particular is especially rare. IMTs infrequently tend to have malignancy. We report a rare case of advanced diaphragmatic parietal pleural IMT with dissemination. A 30-year-old woman complained of right upper abdominal pain. Computed tomography showed a large lobulated mass over the right diaphragm, but no disseminated nodules were noted. Intraoperatively, we found the primary tumor arising from the diaphragmatic parietal pleura and a dozen disseminated nodules, and we removed them completely. The histopathological and immunohistochemical diagnosis was IMT.
Subject(s)
Diaphragm/pathology , Granuloma, Plasma Cell/pathology , Pleura/pathology , Adult , Female , Humans , Immunohistochemistry , Tomography, X-Ray ComputedABSTRACT
OBJECTIVES: Although follow-up surveillance after resection for lung cancer is commonly performed in clinical practice, there is no standard follow-up program. We attempted to establish follow-up examination schedules that we considered would be acceptable to the majority of doctors, and would like to propose them as standard postoperative follow-up pathways. METHODS: We carried out a retrospective analysis of patients' data and reviewed the time of detection of recurrence and the site of recurrence after resection. Published papers were also reviewed. The postoperative follow-up pathways were established based on these data. PROPOSED FOLLOW-UP PATHWAY: The follow-up period was set at as 5 years after resection, and physical examinations, chest radiography, chest CT and blood examination are recommended. Two follow-up pathways were proposed taking the risk of recurrence into consideration: the Risk of recurrence-based pathway and the Comprehensive pathway. In the Risk of recurrence-based pathway, the follow-up examination schedule is modified according to the risk of recurrence. In the Comprehensive pathway, a single universal examination schedule is recommended for all patients. The choice between these two pathways is left to the discretion of the attending doctor. CONCLUSIONS: We proposed two follow-up pathways, based on retrospective analysis of patients' data and a review of published papers, which we considered would be acceptable to the majority of doctors and would be suited to the current medical environment in Japan. A prospective study to evaluate the efficacy of the follow-up pathways is ongoing.
Subject(s)
Lung Neoplasms , Research Design , Follow-Up Studies , Humans , Japan/epidemiology , Lung Neoplasms/diagnosis , Lung Neoplasms/mortality , Lung Neoplasms/surgery , Physical Examination , Postoperative Period , Prospective Studies , Radiography, Thoracic , Survival Rate/trendsABSTRACT
A 54-year-old man with pulmonary non-tuberculous mycobacteriosis( pulmonary NTM) who had been treated by antituberculous chemotherapy, developed a new nodule of 1.3 cm in size in the segment 1/2 of the right upper lobe. The cavity of 3.5 cm in size in the segment 6 of the right lower lobe from which Mycobacterium intracellulare was bronchoscopically detected, was suspected to be pulmonary NTM lesion. Since lung cancer was highly suspected by radiological examinations, right upper lobectomy and S6 segmentectomy were performed. Pathological diagnosis for the right upper lobe nodule was adenocarcinoma.
Subject(s)
Lung Neoplasms/surgery , Mycobacterium avium-intracellulare Infection/surgery , Anti-Bacterial Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biopsy , Combined Modality Therapy , Humans , Lung Neoplasms/complications , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/drug therapy , Male , Middle Aged , Mycobacterium avium-intracellulare Infection/complications , Mycobacterium avium-intracellulare Infection/diagnostic imaging , Mycobacterium avium-intracellulare Infection/drug therapy , Pneumonectomy , Radiography , Treatment OutcomeABSTRACT
The present report describes a case of typical carcinoid tumor with intense fluorodeoxyglucose (FDG) uptake. The most of tumor cells were characterized by eosinophilic cytoplasm resulting from accumulation of mitochondria, which was called an oncocytic carcinoid tumor. Glucose transporter type 1 (GLUT-1) was expressed in a membranous pattern in the oncocytic component. Oncocytic carcinoid tumors could show intense FDG uptake due to the numerous intracellular mitochondria and the membranous overexpression of GLUT-1. Thus, it could be a potential pitfall of interpreting FDG-PET/CT image.
Subject(s)
Carcinoid Tumor/diagnostic imaging , Fluorodeoxyglucose F18 , Lung Neoplasms/diagnostic imaging , Positron-Emission Tomography , Tomography, X-Ray Computed , Aged , Biological Transport , Carcinoid Tumor/metabolism , Fluorodeoxyglucose F18/metabolism , Humans , Lung Neoplasms/metabolism , Male , Multimodal ImagingABSTRACT
BACKGROUND: Patients with lung cancer often present with recurrence, even after resection. The identification of risk factors for recurrence after resection is useful. METHODS: Among 1,338 patients with lung cancer who underwent a complete resection, 277 developed recurrences post surgery. Data regarding the TNM factors, histologic subtype, and presence/absence of vessel invasion were analyzed retrospectively using the survival tree method to identify groups with a high risk of recurrence after resection. RESULTS: The results revealed that the T factor, the N factor, and lymphatic (ly) and blood (v) vessel invasion were related to the risk of recurrence, and six combinations of these factors were identified using the survival tree method: group A: v = 0, T ≤ 1b, ly = 0; group B: v = 0, T ≤ 1b, ly ≥ 1; group C: v = 0, T ≥ 2a; group D: v ≥ 1, N ≤ 1, T ≤ 2b; group E: v ≥ 1, N ≤ 1, T ≥ 3; and group F: v ≥ 1, N ≥ 2. The six groups were then further classified into three groups: a low-risk group (group A), a moderate-risk group (groups B, C, and D), and a high-risk group (groups E and F). The 5-year recurrence-free survival rate was approximately 98% for the low-risk group, 75% for the moderate-risk group, and 30% for the high-risk group. CONCLUSIONS: Combining the T, N, v, and ly factors allowed the precise identification of a group with a high risk of recurrence after resection.
Subject(s)
Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Non-Small-Cell Lung/surgery , Lung Neoplasms/mortality , Lung Neoplasms/surgery , Neoplasm Recurrence, Local/mortality , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Retrospective Studies , Risk Assessment , Risk Factors , Survival RateABSTRACT
PURPOSE: Follow-up by chest CT is often performed routinely after stereotactic body radiotherapy (SBRT) for primary lung cancer. We investigated how often periodical chest CT detected lung-cancer related chest events (failure in the chest, new primary lung cancer), and how often chest CT follow-ups led to curative intent salvage treatment. MATERIALS AND METHODS: Between 2006 and 2009, 90 stage I primary lung cancers in 86 patients received SBRT. In principle, chest CT was scheduled every 2-3 months in the first two years, and every 3-4 months thereafter. RESULTS: Median time to follow-up by chest CT was 26 months (1-61 months). Twenty-seven lung-cancer related chest events were detected by periodical chest CT after SBRT. The three-year lung-cancer related chest event free rate was 62 %. It was possible to apply curative-intent salvage treatment to 56 % of the lung-cancer related chest events. The two-year overall survival rate was 66 % among the 13 patients who received curative-intent salvage treatment (radiotherapy, 11; surgery, 2). CONCLUSION: Post-SBRT lung-cancer related chest events (as detected by periodical chest CT) were not uncommon (approximately 40 % at 3 years from SBRT), and it was possible to treat more than half of these lesions with curative-intent salvage treatment.
Subject(s)
Adenocarcinoma/diagnostic imaging , Adenocarcinoma/pathology , Carcinoma, Squamous Cell/diagnostic imaging , Carcinoma, Squamous Cell/pathology , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/pathology , Radiosurgery , Tomography, X-Ray Computed , Adenocarcinoma/mortality , Adenocarcinoma/radiotherapy , Adenocarcinoma/therapy , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/radiotherapy , Carcinoma, Squamous Cell/therapy , Disease-Free Survival , Female , Fluorodeoxyglucose F18/pharmacology , Follow-Up Studies , Humans , Incidence , Japan/epidemiology , Lung Neoplasms/mortality , Lung Neoplasms/radiotherapy , Lung Neoplasms/therapy , Male , Middle Aged , Multimodal Imaging , Neoplasm Staging , Positron-Emission Tomography , Radiopharmaceuticals , Retrospective Studies , Salvage Therapy , Survival Rate , Treatment OutcomeABSTRACT
PURPOSE: To identify factors affecting local control of stereotactic body radiotherapy (SBRT) for lung tumors including primary lung cancer and metastatic lung tumors. MATERIALS AND METHODS: Between June 2006 and June 2009, 159 lung tumors in 144 patients (primary lung cancer, 128; metastatic lung tumor, 31) were treated with SBRT with 48-60 Gy (mean 50.1 Gy) in 4-5 fractions. Higher doses were given to larger tumors and metastatic tumors in principle. Assessed factors were age, gender, tumor origin (primary vs. metastatic), histological subtype, tumor size, tumor appearance (solid vs. ground glass opacity), maximum standardized uptake value of positron emission tomography using (18)F-fluoro-2-deoxy-D: -glucose, and SBRT doses. RESULTS: Follow-up time was 1-60 months (median 18 months). The 1-, 2-, and 3-year local failure-free rates of all lesions were 90, 80, and 77 %, respectively. On univariate analysis, metastatic tumors (p < 0.0001), solid tumors (p = 0.0246), and higher SBRT doses (p = 0.0334) were the statistically significant unfavorable factors for local control. On multivariate analysis, only tumor origin was statistically significant (p = 0.0027). The 2-year local failure-free rates of primary lung cancer and metastatic lung tumors were 87 and 50 %, respectively. CONCLUSIONS: A metastatic tumor was the only independently significant unfavorable factor for local control after SBRT.
Subject(s)
Lung Neoplasms/secondary , Lung Neoplasms/surgery , Radiosurgery , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/surgery , Disease-Free Survival , Female , Humans , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/pathology , Male , Multimodal Imaging , Positron-Emission Tomography , Radiotherapy Dosage , Tomography, X-Ray ComputedABSTRACT
BACKGROUND: Patients undergoing pulmonary resection often suffer from a dry, hacking cough, which is usually refractory to opioid cough suppressors such as codeine. The cough is often painful and impairs the quality of life of the patients. The efficacy of an inhaled corticosteroid plus ß2-agonist against the persistent cough after pulmonary resection was evaluated in this study. METHODS: We enrolled 21 patients in this prospective study of the efficacy of an inhaled corticosteroid plus ß2-agonist against persistent cough following pulmonary resection. After baseline evaluation of the severity of the postoperative persistent cough using a visual analog scale (VAS), treatment with an inhaled corticosteroid plus ß2-agonist was initiated and continued for 2 weeks. At the end of the 2 weeks, the cough severity was evaluated again using a VAS. RESULTS: The median grade of cough on the VAS before the start of the inhaled treatment was 4 (range 3-8). At the end of 2 weeks of treatment with an inhaled corticosteroid plus ß2 agonist, the median grade of cough on the VAS decreased from 4 to 1 (range 0-4). As an adverse effect of the inhalation, hoarseness was observed in one patient, which disappeared promptly after discontinuing the inhalations. CONCLUSION: Treatment with an inhaled corticosteroid plus ß2 agonist appeared to be highly effective, without severe adverse effects, against the persistent cough suffered by patients after pulmonary resection.
Subject(s)
Adrenal Cortex Hormones/administration & dosage , Adrenergic beta-2 Receptor Agonists/administration & dosage , Albuterol/analogs & derivatives , Androstadienes/administration & dosage , Antitussive Agents/administration & dosage , Budesonide/administration & dosage , Cough/drug therapy , Ethanolamines/administration & dosage , Pneumonectomy/adverse effects , Administration, Inhalation , Adrenal Cortex Hormones/adverse effects , Adrenergic beta-2 Receptor Agonists/adverse effects , Aged , Albuterol/administration & dosage , Albuterol/adverse effects , Androstadienes/adverse effects , Antitussive Agents/adverse effects , Budesonide/adverse effects , Budesonide, Formoterol Fumarate Drug Combination , Chi-Square Distribution , Cough/diagnosis , Cough/etiology , Drug Combinations , Ethanolamines/adverse effects , Female , Fluticasone-Salmeterol Drug Combination , Formoterol Fumarate , Humans , Japan , Male , Middle Aged , Prospective Studies , Severity of Illness Index , Time Factors , Treatment OutcomeABSTRACT
PURPOSE: There is no recommended standard follow-up program after resection for lung cancer. Under these circumstances, each doctor establishes his or her own follow-up protocol. This questionnaire survey was conducted to grasp the current status of postoperative follow-up in Japan. METHODS: The questionnaire survey was aimed at determining what examinations were performed and at what frequencies in the setting of postoperative follow-up. Based on these results, examinations performed at a frequency of >50% and the time points after resection at which they were performed were selected and presented as components of an average follow-up program. RESULTS: Questionnaires were sent to 44 institutions, and 26 doctors responded to the questionnaire. All 26 of the doctors performed physical examinations, blood examinations, chest radiography, and computed tomography (CT) routinely, but their frequencies varied widely among the doctors. The average frequencies of the follow-up examinations as judged from this survey are as follows: Physical and blood examinations are performed three to four times a year for the first 3 years and twice a year during the next 2 years. CT is scheduled at 6 and 12 months after resection and is repeated annually thereafter. Chest radiography is performed three to four times a year for the first 3 years and once a year thereafter, between the CT examinations. CONCLUSION: The follow-up programs used in clinical practice vary widely among institutions and doctors in terms of the types of examination performed and the frequencies at which they are performed.
Subject(s)
Diagnostic Tests, Routine/statistics & numerical data , Lung Neoplasms/surgery , Neoplasm Recurrence, Local/diagnosis , Postoperative Care/statistics & numerical data , Practice Patterns, Physicians'/statistics & numerical data , Blood Chemical Analysis/statistics & numerical data , Health Care Surveys , Humans , Japan , Lung Neoplasms/pathology , Lung Neoplasms/secondary , Magnetic Resonance Imaging/statistics & numerical data , Physical Examination/statistics & numerical data , Predictive Value of Tests , Radiography, Thoracic/statistics & numerical data , Radionuclide Imaging/statistics & numerical data , Surveys and Questionnaires , Time Factors , Tomography, X-Ray Computed/statistics & numerical data , Treatment OutcomeABSTRACT
We report an extremely rare case of pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma with a pulmonary arteriovenous fistula (PAVF). A 60-year-old woman with vulvar carcinoma was admitted to our hospital for further examination of an abnormal shadow on chest computed tomography (CT). She showed hypoxemia in the arterial blood gas analysis. (18)F-Fluorodeoxyglucose positron emission tomography (FDG-PET) showed consolidations in the left lower lobe and soft-tissue density lesions in the anterior mediastinum. Each lesion showed heterogeneous FDG uptake. Although needle biopsy of these lesions was performed, a pathological diagnosis was not obtained. For the evaluation of hypoxemia, chest contrast-enhanced CT was performed, and a PAVF in the consolidation of the left lower lobe was revealed. For diagnostic and therapeutic purposes, we performed left lower lobectomy under video-assisted thoracoscopic surgery. In the surgical specimen the PAVF measured 3 cm, and histopathological examination revealed pulmonary MALT lymphoma adjacent to the PAVF.
Subject(s)
Arteriovenous Fistula/complications , Lung Neoplasms/complications , Lymphoma, B-Cell, Marginal Zone/complications , Pulmonary Artery , Pulmonary Veins , Arteriovenous Fistula/diagnosis , Arteriovenous Fistula/surgery , Biopsy, Needle , Female , Fluorodeoxyglucose F18 , Humans , Lung Neoplasms/diagnosis , Lung Neoplasms/surgery , Lymphoma, B-Cell, Marginal Zone/diagnosis , Lymphoma, B-Cell, Marginal Zone/surgery , Middle Aged , Pneumonectomy , Positron-Emission Tomography , Pulmonary Artery/surgery , Pulmonary Veins/surgery , Radiopharmaceuticals , Thoracic Surgery, Video-Assisted , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
The safety and perioperative problems of primary lung cancer surgery after curative chemoradiotherapy (CRT) for thoracic esophageal cancer (EC) are controversial. We retrospectively evaluated six patients who had received curative CRT for EC from 2003 to 2009, in whom the lung nodule was identified as a primary lung cancer and who subsequently underwent pulmonary resection. The treatment for EC consisted of chemotherapy with cisplatin and 5-fluorouracil with concurrent curative thoracic radiotherapy (60 Gy). The median age at the surgery was 75 years (range 69-80 years). The median time from radiation to pulmonary resection was 26 months (range 7-70 months). All patients had a predicted postoperative forced expiratory volume in 1 s (FEV(1))% of >40% before lung surgery. The surgical difficulty involves mediastinal lymph node dissection following tissue fibrotic changes after thoracic radiation. Postoperative complications occurred in two patients, and included arrhythmia and empyema. The patient who developed empyema had a massive pericardial effusion after CRT and underwent pericardial fenestration at the time of pulmonary resection. There was no operative mortality. Lung cancer surgery after curative CRT for EC is feasible in carefully evaluated and selected patients.